Yourgene Health PLC represents a values-driven corporate philosophy that prioritizes innovation, collaboration, and excellence in the field of molecular diagnostics. The company is committed to improving global healthcare through advanced genetic testing solutions and personalized medicine. Yourgene Health PLC strives to provide accurate, reliable, and cost-effective testing services that empower healthcare providers and patients alike. With a strong emphasis on research and development, the company constantly aims to push the boundaries of genetic testing technologies to address unmet needs in reproductive health, oncology, and other medical specialties. Yourgene Health PLC's dedication to quality, integrity, and customer satisfaction makes it a trusted and respected name in the healthcare industry.

Yourgene Health PLC is primarily present in numerous countries and regions worldwide. The company operates in the United Kingdom, France, Italy, Spain, Germany, and the United States, among others. With a global presence, Yourgene Health PLC has established strategic partnerships and collaborations to expand its market reach and serve a diverse range of customers. By focusing on international markets, Yourgene Health PLC aims to leverage its innovative genetic testing solutions and reproductive health products to contribute to improved healthcare outcomes globally.

Yourgene Health PLC has achieved several significant milestones in its journey. One of the key accomplishments is the successful development and launch of the proprietary IONA® test, a non-invasive prenatal screening solution. This innovative product has gained recognition worldwide for its accuracy and reliability, revolutionizing prenatal care. Additionally, Yourgene Health PLC has expanded its global presence through strategic partnerships and acquisitions, allowing the company to enter new markets and strengthen its position in the industry. With a strong commitment to research and development, the company continues to introduce cutting-edge solutions, further establishing its reputation as a leader in genetic testing and reproductive health.

Yourgene Health PLC is a leading molecular diagnostics company specializing in non-invasive prenatal testing and a range of reproductive health solutions. Established in 2005, the company, based in Manchester, UK, has expanded globally, acquiring innovative technologies and establishing strategic partnerships. Yourgene Health PLC offers a comprehensive suite of products and services, including genetic testing for cystic fibrosis and male infertility, as well as COVID-19 testing solutions. With its cutting-edge technologies and commitment to advancing personalized medicine, Yourgene Health PLC has become a trusted name in the field of molecular diagnostics, making significant contributions to improving patient care worldwide.

The main competitors of Yourgene Health PLC in the market include Illumina Inc., Natera Inc., and Thermo Fisher Scientific Inc. These companies are also leaders in the genomics and molecular diagnostics industry, offering similar products and services as Yourgene Health PLC. However, Yourgene Health PLC has a distinct advantage with its innovative technologies and solutions for reproductive health and non-invasive prenatal testing (NIPT). With a strong focus on innovation and a comprehensive product portfolio, Yourgene Health PLC continues to position itself as a top player in the market, providing cutting-edge genetic testing solutions to healthcare professionals globally.

Yourgene Health PLC is primarily active in the healthcare industry.

Yourgene Health PLC operates through a comprehensive and innovative business model. The company primarily focuses on molecular diagnostics and genetic analysis solutions. Its core products and services include prenatal and reproductive health testing, oncology precision medicine, and research tools. By utilizing advanced technologies, Yourgene Health PLC offers highly accurate and reliable genetic testing solutions to help individuals and healthcare professionals make informed decisions. With a commitment to improving patient outcomes and promoting personalized healthcare, Yourgene Health PLC has firmly established itself as a leading provider in the field of molecular diagnostics.

Det Yourgene Health P/E-forhold er -0,74.

Yourgene Health KUV er 0,19.

AlleAktien Kvalitetsscore for Yourgene Health er 3/10.

Den forventede Yourgene Health omsætning er 19,49 mio. GBP.

Den forventede Yourgene Health indtjening er -5,06 mio. GBP.

Yourgene Health PLC is a molecular diagnostics company specializing in the development of test kits for prenatal diagnostics, oncology, and reproductive health. The company is based in the UK and has international offices in Taiwan, Singapore, and the USA. In the prenatal diagnostics sector, Yourgene offers reliable and non-invasive methods for diagnosing birth defects and chromosomal anomalies such as Trisomy 21. Their products, like the Sage Prenatal Screening Test, provide an alternative to traditional invasive tests that are more comfortable for pregnant women. In the oncology field, Yourgene offers tests for accurately identifying genetic mutations that are crucial for diagnosis and selecting appropriate treatments. The company collaborates with leading pharmaceutical companies and sells its products in China, among other markets. In the reproductive health sector, Yourgene offers high-quality diagnostic tests for fertility and preimplantation diagnosis. These include the IONA Test for determining the baby's sex chromosomes and the QIAplex Assay for identifying inherited diseases. These tests are valuable for affected couples and healthcare professionals. Yourgene Health PLC markets its products through a strategic combination of direct sales, distributor partnerships, and OEM manufacturing. The company works closely with renowned scientists and researchers and actively participates in the development of new diagnostic methods and technologies. In addition to selling test kits, Yourgene also develops software solutions for clinical data analysis and processing. The company collaborates with the biotechnological data evaluation platform Creoptix to provide tailored solutions for biomedical research and clinical practice. Listed on the London Stock Exchange, Yourgene Health PLC has a strong capital base and a growing international presence. With a strong focus on research and development and expanding its global distribution network, the company will continue to play a significant role in the field of molecular diagnostics and contribute to improving the health of women and children worldwide. Answer: Yourgene Health PLC is a molecular diagnostics company specializing in the development of test kits for prenatal diagnostics, oncology, and reproductive health. It offers non-invasive methods for prenatal screening, tests for identifying genetic mutations in oncology, and high-quality diagnostic tests for fertility and preimplantation diagnosis. The company markets its products through a combination of direct sales, distributor partnerships, and OEM manufacturing. It also develops software solutions for clinical data analysis and collaborates with a biotechnological data evaluation platform. Yourgene Health PLC has a strong capital base and a growing international presence. It aims to improve the health of women and children worldwide.

Yourgene Health udbetaler et udbytte på 0 GBP fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Yourgene Health, eller selskabet udbetaler ikke udbytte.

ISIN'en for Yourgene Health er GB00BN31ZD89.

WKN for Yourgene Health er A116JH.

Tickeren for Yourgene Health er YGEN.L.

I løbet af de sidste 12 måneder betalte Yourgene Health en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Yourgene Health sandsynligvis betale en dividende på 0 GBP.

Udbytteafkastet for Yourgene Health er i øjeblikket .

Yourgene Health betaler kvartalsvis udbytte. Dette uddeles i månederne .

Yourgene Health betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 GBP. Dette svarer til et dividendeafkast på 0 %.

Yourgene Health bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Yourgene Health fra den 14.7.2024 på 0 GBP, skulle du have haft aktien i din portefølje før ex-datoen den 14.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 14.7.2024.

I løbet af 2023 udbetalte Yourgene Health 0 GBP i form af dividender.

Udbytterne fra Yourgene Health udbetales i GBP.